Cargando…

A BIRC5(High) COD1(Low) Cancer Tissue Phenotype Indicates Poorer Prognosis of Metastatic Breast Cancer Patients

Extensive data research is helpful to find sensitive biomarkers for prognostic prediction of metastatic breast cancer. Through analyzing multiple GEO datasets, literature retrieval, and verified in GEPIA datasets, we identify BIRC5 (Baculoviral IAP repeat containing 5) and CDO1 (Cysteine dioxygenase...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Yujie, Yuan, Feng, Yu, Jing, Si, Yibei, Zheng, Yiwen, Li, Dongqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208035/
https://www.ncbi.nlm.nih.gov/pubmed/35734521
http://dx.doi.org/10.1177/11769351221096655
_version_ 1784729654037315584
author Bai, Yujie
Yuan, Feng
Yu, Jing
Si, Yibei
Zheng, Yiwen
Li, Dongqing
author_facet Bai, Yujie
Yuan, Feng
Yu, Jing
Si, Yibei
Zheng, Yiwen
Li, Dongqing
author_sort Bai, Yujie
collection PubMed
description Extensive data research is helpful to find sensitive biomarkers for prognostic prediction of metastatic breast cancer. Through analyzing multiple GEO datasets, literature retrieval, and verified in GEPIA datasets, we identify BIRC5 (Baculoviral IAP repeat containing 5) and CDO1 (Cysteine dioxygenase type 1) as DEGs (differentially expressed genes) between breast tumor and normal tissue and DEGs between metastatic breast cancer and breast cancer in situ. Then, we performed a series of in silico studies on BIRC5 and CDO1 using online tools including the UALCAN, TIMER, TCGA-BRCA, LinkedOmics Kaplan-Meier Plotter, and an R script for analysis. To verify the association of 2 genes expression and patients’ clinical data, we detected BIRC5 and CDO1 mRNA in the tissue of 48 breast cancer patients. The results showed the tumor with BIRC5(high) CDO1(low) expression generally indicated patients’ shorter overall (OS) and relapse-free survival (RFS). Specifically, BIRC5 and CDO1 levels significantly affect OS or RFS in patients with Lymph node metastasis and molecular subtypes of TNBC (triple-negative breast cancer) and Luminal A. A BIRC5(high) tumor displayed a purer tumor purity and expressed more KIR receptors on NK cells while activating more FOXP3(+)CD25(+) Treg cells. The CDO1(low) tumors infiltrated with more immunocytes leading to less tumor purity. In our verified experiment, BIRC5 mRNA level in patients with stage III and over was significantly higher than in patients with stage 0 to II, but there were no significant differences among molecular subtyping groups; TNBC tissue expressed lower CDO1 mRNA level than HER2(+) and Luminal type cancer tissue. In conclusion, a BIRC5(high) CDO1(low) expression type in breast cancer tissue indicates a poorer prognosis of patients. The potential mechanism might be increased BIRC5 expression in cancer tissue is likely to accompany NK cells inhibition, activating more Treg cells, and lacking effective CD8(+) T cells proliferation. Meanwhile, CDO1 level is positively related to more immunocytes infiltration.
format Online
Article
Text
id pubmed-9208035
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-92080352022-06-21 A BIRC5(High) COD1(Low) Cancer Tissue Phenotype Indicates Poorer Prognosis of Metastatic Breast Cancer Patients Bai, Yujie Yuan, Feng Yu, Jing Si, Yibei Zheng, Yiwen Li, Dongqing Cancer Inform Original Research Extensive data research is helpful to find sensitive biomarkers for prognostic prediction of metastatic breast cancer. Through analyzing multiple GEO datasets, literature retrieval, and verified in GEPIA datasets, we identify BIRC5 (Baculoviral IAP repeat containing 5) and CDO1 (Cysteine dioxygenase type 1) as DEGs (differentially expressed genes) between breast tumor and normal tissue and DEGs between metastatic breast cancer and breast cancer in situ. Then, we performed a series of in silico studies on BIRC5 and CDO1 using online tools including the UALCAN, TIMER, TCGA-BRCA, LinkedOmics Kaplan-Meier Plotter, and an R script for analysis. To verify the association of 2 genes expression and patients’ clinical data, we detected BIRC5 and CDO1 mRNA in the tissue of 48 breast cancer patients. The results showed the tumor with BIRC5(high) CDO1(low) expression generally indicated patients’ shorter overall (OS) and relapse-free survival (RFS). Specifically, BIRC5 and CDO1 levels significantly affect OS or RFS in patients with Lymph node metastasis and molecular subtypes of TNBC (triple-negative breast cancer) and Luminal A. A BIRC5(high) tumor displayed a purer tumor purity and expressed more KIR receptors on NK cells while activating more FOXP3(+)CD25(+) Treg cells. The CDO1(low) tumors infiltrated with more immunocytes leading to less tumor purity. In our verified experiment, BIRC5 mRNA level in patients with stage III and over was significantly higher than in patients with stage 0 to II, but there were no significant differences among molecular subtyping groups; TNBC tissue expressed lower CDO1 mRNA level than HER2(+) and Luminal type cancer tissue. In conclusion, a BIRC5(high) CDO1(low) expression type in breast cancer tissue indicates a poorer prognosis of patients. The potential mechanism might be increased BIRC5 expression in cancer tissue is likely to accompany NK cells inhibition, activating more Treg cells, and lacking effective CD8(+) T cells proliferation. Meanwhile, CDO1 level is positively related to more immunocytes infiltration. SAGE Publications 2022-06-14 /pmc/articles/PMC9208035/ /pubmed/35734521 http://dx.doi.org/10.1177/11769351221096655 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Bai, Yujie
Yuan, Feng
Yu, Jing
Si, Yibei
Zheng, Yiwen
Li, Dongqing
A BIRC5(High) COD1(Low) Cancer Tissue Phenotype Indicates Poorer Prognosis of Metastatic Breast Cancer Patients
title A BIRC5(High) COD1(Low) Cancer Tissue Phenotype Indicates Poorer Prognosis of Metastatic Breast Cancer Patients
title_full A BIRC5(High) COD1(Low) Cancer Tissue Phenotype Indicates Poorer Prognosis of Metastatic Breast Cancer Patients
title_fullStr A BIRC5(High) COD1(Low) Cancer Tissue Phenotype Indicates Poorer Prognosis of Metastatic Breast Cancer Patients
title_full_unstemmed A BIRC5(High) COD1(Low) Cancer Tissue Phenotype Indicates Poorer Prognosis of Metastatic Breast Cancer Patients
title_short A BIRC5(High) COD1(Low) Cancer Tissue Phenotype Indicates Poorer Prognosis of Metastatic Breast Cancer Patients
title_sort birc5(high) cod1(low) cancer tissue phenotype indicates poorer prognosis of metastatic breast cancer patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208035/
https://www.ncbi.nlm.nih.gov/pubmed/35734521
http://dx.doi.org/10.1177/11769351221096655
work_keys_str_mv AT baiyujie abirc5highcod1lowcancertissuephenotypeindicatespoorerprognosisofmetastaticbreastcancerpatients
AT yuanfeng abirc5highcod1lowcancertissuephenotypeindicatespoorerprognosisofmetastaticbreastcancerpatients
AT yujing abirc5highcod1lowcancertissuephenotypeindicatespoorerprognosisofmetastaticbreastcancerpatients
AT siyibei abirc5highcod1lowcancertissuephenotypeindicatespoorerprognosisofmetastaticbreastcancerpatients
AT zhengyiwen abirc5highcod1lowcancertissuephenotypeindicatespoorerprognosisofmetastaticbreastcancerpatients
AT lidongqing abirc5highcod1lowcancertissuephenotypeindicatespoorerprognosisofmetastaticbreastcancerpatients
AT baiyujie birc5highcod1lowcancertissuephenotypeindicatespoorerprognosisofmetastaticbreastcancerpatients
AT yuanfeng birc5highcod1lowcancertissuephenotypeindicatespoorerprognosisofmetastaticbreastcancerpatients
AT yujing birc5highcod1lowcancertissuephenotypeindicatespoorerprognosisofmetastaticbreastcancerpatients
AT siyibei birc5highcod1lowcancertissuephenotypeindicatespoorerprognosisofmetastaticbreastcancerpatients
AT zhengyiwen birc5highcod1lowcancertissuephenotypeindicatespoorerprognosisofmetastaticbreastcancerpatients
AT lidongqing birc5highcod1lowcancertissuephenotypeindicatespoorerprognosisofmetastaticbreastcancerpatients